Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke

Journal of Neuroendocrinology

Volumn 25, Issue 9, 2013, Pages 771-778

  Tu, W J ^a   Dong, X ^b   Zhao, S J ^c   Yang, D G ^a   Chen, H ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c CHINA REHABILITATION RESEARCH CENTER   (China)

Author keywords

Acute ischaemic stroke; Biomarker; Neuroendocrine; Prognostic

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; COPEPTIN; HYDROCORTISONE;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROENDOCRINOLOGY; OUTCOME ASSESSMENT; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ACUTE ISCHAEMIC STROKE; BIOMARKER; NEUROENDOCRINE; PROGNOSTIC;

AGED; BIOLOGICAL MARKERS; BRAIN; BRAIN ISCHEMIA; FEMALE; GLYCOPEPTIDES; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NEUROIMAGING; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 84882721794     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/jne.12052     Document Type: Article

References (39)

1. Bonita R, Mendis S, Truelsen T, Bogousslavsky J, Toole J, Yatsu F. The global stroke initiative. Lancet Neurol 2004; 3: 391-393.
2. Josephson SA, Hills NK, Johnston SC. NIH Stroke Scale reliability in ratings from a large sample of clinicians. Cerebrovasc Dis 2006; 22: 389-395.
3. Sato S, Toyoda K, Uehara T, Toratani N, Yokota C, Moriwaki H, Naritomi H, Minematsu K. Baseline NIH Stroke Scale Score predicting outcome in anterior and posterior circulation strokes. Neurology 2008; 70: 2371-2377.
4. Katan M, Elkind MS. Inflammatory and neuroendocrine biomarkers of prognosis after ischemic stroke. Expert Rev Neurother 2011; 11: 225-239.
5. Feibel JH, Hardy PM, Campbell RG, Goldstein MN, Joynt RJ. Prognostic value of the stress response following stroke. JAMA 1977; 238: 1374-1376.
6. Nakagawa K, Yamaguchi T, Seida M, Yamada S, Imae S, Tanaka Y, Yamamoto K, Ohno K. Plasma concentrations of brain natriuretic peptide in patients with acute ischemic stroke. Cerebrovasc Dis 2005; 19: 157-164.
7. Etgen T, Baum H, Sander K, Sander D. Cardiac troponins and N-terminal pro-brain natriuretic peptide in acute ischemic stroke do not relate to clinical prognosis. Stroke 2005; 36: 270-275.
8. Iltumur K, Yavavli A, Apak I, Ariturk Z, Toprak N. Elevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke. Am Heart J 2006; 151: 1115-1122.
9. Whiteley W, Rumley A, Sattar N, Wardlaw JM, Lowe GDO, Welsh P, Green A, Sandercock PAG, Dennis MS. POS11 blood markers and poor outcome after acute cerebrovascular disease: a prospective cohort study. J Neurol Neurosurg Psychiatry 2010; 81: e70.
10. Montaner J, Perea-Gainza M, Delgado P, Ribó M, Chacón P, Rosell A, Quintana M, Palacios ME, Molina CA, Alvarez-Sabín J. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008; 39: 2280-2287.
11. Anne M, Juha K, Timo M, Mikko T, Olli V, Kyösti S, Heikki H, Vilho M. Neurohormonal activation in ischemic stroke: effects of acute phase disturbances on long-term mortality. Curr Neurovasc Res 2007; 4: 170-175.
12. Neidert S, Katan M, Schuetz P, Fluri F, Ernst A, Bingisser R, Kappos L, Engelter ST, Steck A, Müller B, Christ-Crain M. Anterior pituitary-axis hormones and outcome in acute ischemic stroke. J Intern Med 2011; 269: 420-432.
13. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, Müller K, Meckel S, Gass A, Kappos L, Steck AJ, Engelter ST, Müller B, Christ-Crain M. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009; 66: 799-808.
14. Urwyler SA, Schuetz P, Fluri F, Morgenthaler NG, Zweifel C, Bergmann A, Bingisser R, Kappos L, Steck A, Engelter S, Müller B, Christ-Crain M, Katan M. Prognostic value of copeptin: one-year outcome in patients with acute stroke. Stroke 2010; 41: 1564-1567.
15. Katan M, Nigro N, Fluri F, Schuetz P, Morgenthaler NG, Jax F, Meckel S, Gass A, Bingisser R, Steck A, Kappos L, Engelter S, Müller B, Christ-Crain M. Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology 2011; 76: 563-566.
16. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976; 54: 541-553.
17. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh III EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
18. Brott T, Marler JR, Olinger CP, Adams HP Jr, Tomsick T, Barsan WG, Biller J, Eberle R, Hertzberg V, Walker M. Measurements of acute cerebral infarction: lesion size by computed tomography. Stroke 1989; 20: 871-875.
19. Bonita R, Beaglehole R. Modification of Rankin Scale: recovery of motor function after stroke. Stroke 1988; 19: 1497-1500.
20. Statistics Notes The odds ratio. BMJ 2000; 320:1468.1
21. Bruno A, Biller J, Adams Jr HP, Clarke WR, Woolson RF, Williams LS, Hansen MD. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology 1999; 52: 280-284.
22. Czlonkowska A, Ryglewicz D, Lechowicz W. Basic analytical parameters as the predictive factors for 30-day case fatality rate in stroke. Acta Neurol Scand 1997; 95: 121-124.
23. Ramos-Fernandez M, Bellolio MF, Stead LG. Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis 2011; 20: 47-54.
24. Smedbakken L, Jensen JK, Hallén J, Atar D, Januzzi JL, Halvorsen B, Aukrust P, Ueland T. Activated leukocyte cell adhesion molecule and prognosis in acute ischemic stroke. Stroke 2011; 42: 2453-2458.
25. Seet RC, Lee CY, Chan BP, Sharma VK, Teoh HL, Venketasubramanian N, Lim EC, Chong WL, Looi WF, Huang SH, Ong BK, Halliwell B. Oxidative damage in ischemic stroke revealed using multiple biomarkers. Stroke 2011; 42: 2326-2329.
26. Dassan P, Keir G, Brown MM. Criteria for a clinically informative serum biomarker in acute ischaemic stroke: a review of S100B. Cerebrovasc Dis 2009; 27: 295-302.
27. Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, Wardlaw J, Dennis M, Sudlow C. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med 2009; 6: e1000145.
28. Song IU, Kim JS, Kim YI, Lee KS, Jeong DS, Chung SW. Relationship between high-sensitivity C-reactive protein and clinical functional outcome after acute ischemic stroke in a Korean population. Cerebrovasc Dis 2009; 28: 545-550.
29. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006; 166: 2073-2080.
30. Huang Y, Jing J, Zhao XQ, Wang CX, Wang YL, Liu GF, Wang CJ, Liu LP, Yang XM, Jiao Y, Jiao Y, Wang LS, Wang YJ, Gu WK. High-sensitivity C-reactive protein is a strong risk factor for death after acute ischemic stroke among Chinese. CNS Neurosci Ther 2012; 18: 261-266.
31. Campos F, Rodríguez-Yáñez M, Castellanos M, Arias S, Pérez-Mato M, Sobrino T, Blanco M, Serena J, Castillo J. Blood levels of glutamate oxaloacetate transaminase are more strongly associated with good outcome in acute ischaemic stroke than glutamate pyruvate transaminase levels. Clin Sci (Lond) 2011; 121: 11-17.
32. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-2639.
33. Shibazaki K, Kimura K, Okada Y, Iguchi Y, Uemura J, Terasawa Y, Aoki J. Plasma brain natriuretic peptide as an independent predictor of in-hospital mortality after acute ischemic stroke. Intern Med 2009; 48: 1601-1606.
34. De Marchis GM, Katan M, Weck A, Brekenfeld C, Mattle HP, Buhl D, Müller B, Christ-Crain M, Arnold M. Copeptin and risk stratification in patients with ischemic stroke and transient ischemic attack: The CoRisk Study. Int J Stroke 2013; 8: 214-8.
35. Zhang X, Lu XM, Huang LF, Ye H. Copeptin is associated with one-year mortality and functional outcome in patients with acute spontaneous basal ganglia hemorrhage. Peptides 2012; 33: 336-41.
36. Zweifel C, Katan M, Schuetz P, Siegemund M, Morgenthaler NG, Merlo A, Mueller B, Christ-Crain M. Copeptin is associated with mortality and outcome in patients with acute intra- cerebral hemorrhage. BMC Neurol 2010; 26: 34.
37. Sacco RL, Boden-Albala B, Chen X, Lin IF, Kargman DE, Paik MC. Relationship of 6-month functional outcome and stroke severity: implications for acute stroke trials from the Northern Manhattan Stroke Study [abstract]. Neurology 1998; 50: A327.
38. Adams HP Jr, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, Woolson RF, Hansen MD. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999; 53: 126-131.
39. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330: 625.